![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The joint venture collaboration comprises 13 brands across 6 therapeutic areas primarily focused on pain management, including Abstral (fentanyl) and PecFent for breakthrough cancer pain, Moventig for opioid-induced constipation, and Adcal-D3® for osteoporosis.
Lead Product(s): Fentanyl
Therapeutic Area: Neurology Product Name: Abstral
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Grunenthal
Deal Size: $83.2 million Upfront Cash: Undisclosed
Deal Type: Collaboration August 02, 2023